Our current clinical projects

Proprietary projects

Project & Mechanism
Disease areas
Research
Preclinical
Phase I
Phase II
Phase III
Market

Fostroxacitabine bralpamide (fostrox)

Nucleotide DNA polymerase inhibitor (oral)

Hepatocellular carcinoma1)

Hepatocellular carcinoma2)

1) Monotherapy study

2) Combination study

Projects for licensing

Project & Mechanism
Disease areas
Research
Preclinical
Phase I
Phase II
Phase III
Market

Remetinostat

HDAC inhibitor (topical)

Cutaneous T-cell lymphoma (MF)

Squamous cell carcinoma1)

Basal cell carcinoma1)

MIV-711

Cathepsin K inhibitor (oral)

Osteoarthritis

1) Investigator sponsored study at Stanford U.

Outlicensed projects

Project & Mechanism
Disease areas
Research
Preclinical
Phase I
Phase II
Phase III
Market

Birinapant/IGM-8444

SMAC mimetic (intravenous)

Solid tumors

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

Labial herpes

USP-1

Partner: Tango Therapeutics

Cancer

USP-7

Partner: Ubiquigent

Cancer

Our current clinical projects

Proprietary

Fostroxacitabine bralpamide (fostrox)

Nucleotide DNA polymerase inhibitor (oral)

  • Mechanism

    Nucleotide DNA polymerase inhibitor (oral)

  • Disease area

    Hepatocellular carcinoma1)

    Phase I

    Hepatocellular carcinoma2)

    Phase II

1) Monotherapy study

2) Combination study

Partnerships

Birinapant/IGM-8444

SMAC mimetic (intravenous)

  • Mechanism

    SMAC mimetic (Intravenous)

  • Disease area

    Solid tumors

    Phase I

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

  • Mechanism

    Hydrocortisone and aciclovir combination

  • Disease area

    Labial herpes

    Market

USP-1

Partner: Tango Therapeutics

  • Mechanism

  • Disease area

    Cancer

    Preclinical

USP-7

Partner: Ubiquigent

  • Mechanism

  • Disease area

    Cancer

    Preclinical